OGN: Organon Corp Net earnings per share growth forecast for next year

Graphic logo of Organon & Co. (OGN)

Organon & Co. sources raw materials from external partners and utilizes CMOs for distribution, maintaining quality control through GMP. The company has delegated a portion of production and testing to contractors to accelerate logistics. This chart of the consensus EPS n+1 forecast reflects market expectations, where the 8.30 mark indicates the level of current valuations. Biosimilars serve as a steady cash cow, while the launch of new therapy lines will act as a future growth catalyst.

Organon & Co (OGN): Expected earnings per share trend next year from 07/04/2022 to 11/12/2026

Analytical breakdowns and data insights for company organon.com (OGN)

- price and consensus price forecast:
Price Chart Organon Corp|OGN - Broker Consensus Forecast
- market capitalization information:
Market Value Organon|OGN - Total Enterprise Value
- company book value details:
Net Assets per Single Share Organon|OGN - Accounting Value of Company|Market Capitalization to Book Value Ratio organon.com|OGN - Company Balance Sheet Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Organon & Co.|OGN - Long-Term Debt to Capital|Short-Term Debt to Equity Organon|OGN - Company Aggregate Debt|Debt to Book Capitalization Ratio Organon|OGN - Long-Term Debt|Company Short-Term Debt Organon|Quick Liquidity Indicator organon.com
- net income and valuation ratios data:
OGN - Final Profit|Net Profit Forecast Organon & Co.|OGN - Market Price to Net Income Ratio|Projected Price to Earnings Organon & Co.|OGN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Organon|OGN - Operating profit before deduction of amortization|Earnings per share for the last twelve months Organon|OGN - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months organon.com|OGN - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Organon & Co.
General company analysis:OGN, Organon Corp
Finished products of Organon

To objectively assess the operational efficiency of Organon & Co. (OGN), investors must track consensus earnings forecasts that reflect the impact of expansion into China and the success of biosimilars. This assessment of expected EPS growth for the coming year captures the daily dynamics of institutional expectations, allowing for the differentiation of short-term spikes from a sustainable trend toward deleveraging and long-term increases in shareholder value.

Competitors of Organon & Co.

Net earnings per share growth forecast for next year Dare Bioscience Inc.|Projected earnings per share growth rate for next year TXMD (TherapeuticsMD Corp)|Net earnings per share growth forecast for next year Palatin Technologies (PTN)